

Table 4.26

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	77,883	99.9%	58,870	99.9%	9,149	99.9%	8,401	99.9%	306	100.0%	8,297	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>e</sup>	66,284	85.0%	49,479	84.0%	8,046	87.9%	7,615	90.6%	270	88.2%	7,115	85.6%
Cribriform carcinoma <i>in situ</i> (8201/2)	7,009	9.0%	5,171	8.8%	863	9.4%	861	10.2%	18	5.9%	742	8.9%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,636	7.2%	4,353	7.4%	577	6.3%	615	7.3%	27	8.8%	508	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	20,775	26.6%	15,828	26.9%	2,441	26.7%	2,074	24.7%	104	34.0%	2,209	26.6%
Comedocarcinoma <i>in situ</i> (8501/2)	6,493	8.3%	4,846	8.2%	745	8.1%	798	9.5%	33	10.8%	678	8.2%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,132	1.5%	762	1.3%	208	2.3%	139	1.7%	-	-	122	1.5%
Noninfiltrating intracystic carcinoma(8504/2)	255	0.3%	162	0.3%	42	0.5%	49	0.6%	-	-	28	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,210	1.6%	926	1.6%	162	1.8%	102	1.2%	-	-	138	1.7%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	23,587	30.3%	17,299	29.4%	2,997	32.7%	2,934	34.9%	82	26.8%	2,673	32.2%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	9,076	11.6%	7,418	12.6%	812	8.9%	560	6.7%	32	10.5%	933	11.2%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	9,063	11.6%	7,410	12.6%	808	8.8%	560	6.7%	31	10.1%	932	11.2%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	-	-	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,016	2.6%	1,602	2.7%	228	2.5%	162	1.9%	-	-	195	2.3%
Other adenocarcinomas <sup>g</sup>	499	0.6%	367	0.6%	62	0.7%	61	0.7%	-	-	54	0.7%
Other <i>in situ</i> histologies <sup>h</sup>	77	0.1%	59	0.1%	-	-	-	-	-	-	-	-
Total	77,960	100.0%	58,929	100.0%	9,155	100.0%	8,407	100.0%	306	100.0%	8,308	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>f</sup> CIS = Carcinoma *in situ*.

<sup>g</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.